Hi SF,

I think we all realize an announcement of some sorts is coming, however another dilutive PP is not the optimum option for a company halfway through a  Phase 3 study who has yet to ink a deal with a large Multinational BP,  I would rather at least see a partnership deal, license deal or a prized CVR deal rather  than a continual finance deal(PP), going down the same road, Retail Shareholders wil not be as rewarded ith that type of deal

From Zacks reseach dept, March 27/2017 (which i don't carry that much faith in  credibility wise but its all we ahve at this point)

We note that at current cash burn rates, Resverlogix will need to raise cash prior to the end of the fiscal year. Management has outlined several financial options that they are currently exploring which we list below: Co-development or follow on compounds with major pharmaceutical company would provide upfront payment and coverage of future expenses. Licensing on a regional basis would provide upfront payments Licensing certain new or orphan indications to partners for upfront payment Partnering and offering first right of refusal in an M&A transaction for an upfront payment Private placements with equity and warrants Public offering of equity, potentially with an IPO on a US Exchange (less likely) Debt financing (less likely) We anticipate that Resverlogix will favor the options in the order they are presented above and expect execution on one or more in the next months. 

GLTA